Abstract
Background Bloodstream infections (BSI) are a major global health concern, and existing diagnostic methods are too slow to guide targeted antibiotic therapy for critically ill patients, risking poor clinical outcomes. Rapid metagenomic-sequencing (mNGS) can facilitate swift pathogen and antimicrobial resistance (AMR) detection, but identification is challenged by significant host versus bacterial DNA in blood. To accelerate microbiological diagnosis, we developed M-15, a rapid and modular mNGS-based host DNA depletion workflow, validated with suspected BSI blood-culture samples and rapid culture-enriched spiked blood.
Methods To assess chemical host DNA depletion (CHDD) efficiency, M-15 was benchmarked with five commercial/published protocols. Later, M-15 was combined with rapid mNGS with/without adaptive sampling (AS) and tested on clinical blood-culture samples (n=33) from suspected BSI cases identified on BACT/ALERT VIRTUO (30 flagged positive, three remained negative). To determine whether it is possible to utilise M-15 mNGS prior to blood-culture flagging positive, a rapid enrichment method was tested starting with 1-10 colony forming units of the top 15 bacterial species causing BSI spiked into BACTEC medium enriched with 10 mL sheep blood.
Results All six chemical depletion protocols reduced host DNA by 2.5×100 to 4.1×106-fold, with the in-house M-15 protocol performing best, while adaptive sampling depleted host >5-fold. With BACT/ALERT specimens, M-15 mNGS accurately identified 3/3 negative, 28/28 mono-bacterial, and 2/4 multi-bacterial species. With rapid culture-enrichment and M-15 mNGS, <18% DNA was classified as host and all bacterial species tested (n=10) were correctly identified. M-15 mNGS accurately predicted phenotypic AMR/susceptibility for 90.3% (232/257) of drug/bacteria combinations from BACT/ALERT positive samples.
Conclusions This study demonstrates that M-15 mNGS can facilitate species and AMR gene detection within 5-7 hours of BACT/ALERT positivity. Including 8-hour culture enrichment, microbiological and AMR confirmation is possible within 13-15 hours of sample collection. Thus, the M-15 mNGS workflow has the potential to improve patient outcomes in BSI.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Royal Society Research Grant (RGS\R1\211163) and University of Glasgows Lord Kelvin Adam Smith (LKAS) Ph.D. studentship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and approved by the University of Glasgow College of Medical, Veterinary & Life Sciences Ethics Committee (Project No: 200210015) and UK National Health Services (NHS) Greater Glasgow and Clyde (R&I reference: GN19ID331). No personal information from the patients and healthy volunteers was collected and used in this study. Human DNA reads obtained from mNGS were excluded or not utilised for any bioinformatics analyses beyond quantifying the number of hosts reads generated.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Abbreviations
- AMR
- Antimicrobial resistance
- AS
- Adaptive sampling
- AST
- Antimicrobial susceptibility testing
- ATCC
- American Type Culture Collection
- BSI
- Bloodstream infection
- BPM
- Bases per million
- CFU
- Colony-forming units
- CHDD
- Chemical host DNA depletion ds
- DNA
- Double-stranded DNA
- EUCAST
- European Committee on Antimicrobial Susceptibility Testing
- FDA
- Food and Drug Administration (USA)
- GC%
- Guanine-cytosine content percentage
- mNGS
- Metagenomic next-generation sequencing
- Mbp
- Megabase pairs
- MDA
- Multiple displacement amplification
- NHS
- National Health Service (UK)
- ONT
- Oxford Nanopore Technologies
- PBS
- Phosphate-buffered saline
- qPCR
- Quantitative polymerase chain reaction
- RBC
- Red blood cells
- WGA
- Whole-genome amplification
- WGS
- Whole-genome sequencing
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos